Cambridge Cognition Holdings PLC Alzheimer's drug potential for Cambridge Cognition

TIDMCOG

Cambridge Cognition Holdings PLC

25 October 2019

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Renewed promise for early Alzheimer's drug signals potential for Cambridge Cognition's assessment solution

Following a consultation with the U.S. Food and Drug Administration ("FDA"), Biogen (Nasdaq : BIIB) and Eisai, Co., Ltd (Tokyo, Japan) have announced plans to pursue regulatory approval for aducanumab, which would be the first therapy to tackle clinical decline in early Alzheimer's disease. If successful, this presents an opportunity for Cambridge Cognition whose CANTAB(TM) assessments are specifically sensitive to the early cognitive decline during Alzheimer's disease.

Despite initial concerns about the efficacy of aducanumab, new analysis of an expanded dataset has revealed positive results at higher doses of the drug and Biogen have indicated that they will file for approval in the U.S. early next year. If approved, this will be the first drug to slow the progression of Alzheimer's disease; a major therapeutic breakthrough, as there have been no new treatments approved since 2003.

This promising step forward for Alzheimer's disease raises the urgent challenge of finding and assessing patients who are most likely to benefit from such drugs. Cambridge Cognition's CANTAB Mobile(TM) can support clinicians in making this decision.

CANTAB Mobile(TM) delivers an automated memory assessment and depression scale to distinguish older patients who have concerns about their memory from those at increased risk of dementia. Available in over 20 languages, this CE-marked, FDA-cleared and TGA-approved medical device is poised to help clinicians all over the world identify patients who are most likely to benefit from disease-modifying treatments.

Matthew Stork, Chief Executive Officer of Cambridge Cognition, said:

"We were delighted to hear the news of Biogen's re-invigorated Alzheimer's programme, as it holds promise for the millions of people worldwide who are affected by the disease. We are therefore preparing for the approval of disease modifying treatments so that patients and families can benefit from new therapies as soon as possible. CANTAB Mobile(TM) is a medical device that can help clinicians in identifying the right patients for these potential new treatments."

For further information, contact:

 
 Cambridge Cognition Holdings PLC              Tel: [phone] 
  Matthew Stork, Chief Executive Officer        [e-mail] 
  Nick Walters, Chief Financial Officer 
 finnCap Ltd (NOMAD and Joint Broker)          Tel: [phone] 
  Geoff Nash / Simon Hicks                      (Corporate Finance) 
  Alice Lane / Manasa Patil                     (Corporate Broking) 
 Dowgate Capital Limited (Joint Broker)        Tel: [phone] 
  David Poutney / James Serjeant 
 IFC Advisory Ltd (Financial PR and IR)        Tel: [phone] 
  Tim Metcalfe / Graham Herring / Zach Cohen 
 

Notes to Editors

About Cambridge Cognition

Cambridge Cognition is a neuroscience technology company developing digital health products to better understand, detect and treat conditions affecting brain health. The company's software products assess cognitive health in patients worldwide to improve clinical trial outcomes, identify and stratify patients early and improve global efficiency in pharmaceutical and healthcare industries.

For further information visit www.cambridgecognition.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

NRAEAXELAEENFFF

(END) Dow Jones Newswires

October 25, 2019 02:00 ET (06:00 GMT)